New Safety Information for Colchicine (marketed as Colcrys)

New Safety Information for Colchicine (marketed as Colcrys)
July 30, 2009
Audience: Rheumatological healthcare professionals.

FDA notified healthcare professionals of the approval of the first
single-ingredient oral colchicine product, Colcrys, for the treatment
of familial Mediterranean fever (FMF) and acute gout flares and of two
previously uncharacterized safety concerns associated with the use of
colchicine. Oral colchicine has been used for many years as an
unapproved drug with no FDA-approved prescribing information, dosage
recommendations, or drug interaction warnings.